Pharmacological Management of Muscle Cramps

First-Line Treatments

The American Association for the Study of Liver Diseases recommends baclofen (starting at 10 mg/day with weekly increases of 10 mg/day up to 30 mg/day) for treating muscle cramps, particularly in patients with liver disease 1, 2, 3
The European Association for the Study of the Liver (EASL) guidelines recommend human albumin infusion (20-40 g/week) for muscle cramps, especially in patients with cirrhosis 1, 4, 3
Non-pharmacological interventions such as stretching, massaging the affected muscles, and application of ice are recommended to accompany drug therapy 3

The American Geriatrics Society recommends muscle relaxants like methocarbamol for skeletal muscle pain, though their effects are nonspecific and not directly related to muscle relaxation 5, 6, 3
Benzodiazepines have limited efficacy for muscle cramps but may be justified for trials in relief of muscle spasm, especially when anxiety, muscle spasm, and pain coexist 5, 6

Baclofen (10-30 mg/day) is particularly recommended for patients with cirrhosis experiencing muscle cramps 1, 2, 4
The EASL guidelines recommend albumin infusion for patients with liver disease experiencing muscle cramps 1, 2, 4
Diuretics should be discontinued if incapacitating muscle cramps develop in patients with liver disease 1, 4

Muscle relaxants like cyclobenzaprine should be used with caution in older adults due to increased risk of falls 5, 6
Benzodiazepines carry a high risk profile in older adults and should be used cautiously 6
Correction of electrolyte abnormalities, especially hypokalemia and hypomagnesemia, is crucial in treating muscle cramps in older adults 3

Cyclobenzaprine should not be prescribed with the mistaken belief that it directly relieves muscle spasm 5, 6
Quinidine at 400 mg/day is associated with significant side effects including diarrhea in about one-third of cases requiring treatment withdrawal 2

For patients on baclofen, monitor for common side effects including dizziness, somnolence, and gastrointestinal symptoms 5, 6
When discontinuing baclofen after prolonged use, implement a slow tapering period to prevent withdrawal symptoms 5, 6
In patients with cirrhosis, monitor serum creatinine, sodium, and potassium during treatment, especially during the first month 1, 2
For patients with muscle cramps related to electrolyte disturbances, regular monitoring of electrolyte levels is essential 3

The American Geriatrics Society recommends starting baclofen at 5mg up to three times daily (total 15mg/day maximum initially) in geriatric populations, with careful monitoring for muscle weakness, urinary dysfunction, cognitive effects, and sedation 7
For alcohol use disorder in patients with cirrhosis, a therapeutic dose of 30mg/day has been studied and found effective, with a regimen of 10mg three times daily 8

The appropriate starting dose depends on patient age, with older adults starting at 5mg up to three times daily, and renal function, as baclofen is primarily renally excreted 7
Concurrent medications, such as tizanidine, require monitoring for drug-drug interactions 7

Key adverse effects to monitor include dizziness, somnolence, cognitive impairment, muscle weakness, urinary dysfunction, and orthostatic hypotension 7
Worsening mental status, particularly in patients at risk for hepatic encephalopathy, is also a concern 8

When discontinuing baclofen after prolonged use, a slow tapering period is necessary to prevent withdrawal symptoms, and abrupt discontinuation can cause central nervous system irritability 7